Chapter 5.15 Trichloroethylene
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Pharmacology – Inhalant Anesthetics
Pharmacology- Inhalant Anesthetics Lyon Lee DVM PhD DACVA Introduction • Maintenance of general anesthesia is primarily carried out using inhalation anesthetics, although intravenous anesthetics may be used for short procedures. • Inhalation anesthetics provide quicker changes of anesthetic depth than injectable anesthetics, and reversal of central nervous depression is more readily achieved, explaining for its popularity in prolonged anesthesia (less risk of overdosing, less accumulation and quicker recovery) (see table 1) Table 1. Comparison of inhalant and injectable anesthetics Inhalant Technique Injectable Technique Expensive Equipment Cheap (needles, syringes) Patent Airway and high O2 Not necessarily Better control of anesthetic depth Once given, suffer the consequences Ease of elimination (ventilation) Only through metabolism & Excretion Pollution No • Commonly administered inhalant anesthetics include volatile liquids such as isoflurane, halothane, sevoflurane and desflurane, and inorganic gas, nitrous oxide (N2O). Except N2O, these volatile anesthetics are chemically ‘halogenated hydrocarbons’ and all are closely related. • Physical characteristics of volatile anesthetics govern their clinical effects and practicality associated with their use. Table 2. Physical characteristics of some volatile anesthetic agents. (MAC is for man) Name partition coefficient. boiling point MAC % blood /gas oil/gas (deg=C) Nitrous oxide 0.47 1.4 -89 105 Cyclopropane 0.55 11.5 -34 9.2 Halothane 2.4 220 50.2 0.75 Methoxyflurane 11.0 950 104.7 0.2 Enflurane 1.9 98 56.5 1.68 Isoflurane 1.4 97 48.5 1.15 Sevoflurane 0.6 53 58.5 2.5 Desflurane 0.42 18.7 25 5.72 Diethyl ether 12 65 34.6 1.92 Chloroform 8 400 61.2 0.77 Trichloroethylene 9 714 86.7 0.23 • The volatile anesthetics are administered as vapors after their evaporization in devices known as vaporizers. -
Reactions of Benzene & Its Derivatives
Organic Lecture Series ReactionsReactions ofof BenzeneBenzene && ItsIts DerivativesDerivatives Chapter 22 1 Organic Lecture Series Reactions of Benzene The most characteristic reaction of aromatic compounds is substitution at a ring carbon: Halogenation: FeCl3 H + Cl2 Cl + HCl Chlorobenzene Nitration: H2 SO4 HNO+ HNO3 2 + H2 O Nitrobenzene 2 Organic Lecture Series Reactions of Benzene Sulfonation: H 2 SO4 HSO+ SO3 3 H Benzenesulfonic acid Alkylation: AlX3 H + RX R + HX An alkylbenzene Acylation: O O AlX H + RCX 3 CR + HX An acylbenzene 3 Organic Lecture Series Carbon-Carbon Bond Formations: R RCl AlCl3 Arenes Alkylbenzenes 4 Organic Lecture Series Electrophilic Aromatic Substitution • Electrophilic aromatic substitution: a reaction in which a hydrogen atom of an aromatic ring is replaced by an electrophile H E + + + E + H • In this section: – several common types of electrophiles – how each is generated – the mechanism by which each replaces hydrogen 5 Organic Lecture Series EAS: General Mechanism • A general mechanism slow, rate + determining H Step 1: H + E+ E El e ctro - Resonance-stabilized phile cation intermediate + H fast Step 2: E + H+ E • Key question: What is the electrophile and how is it generated? 6 Organic Lecture Series + + 7 Organic Lecture Series Chlorination Step 1: formation of a chloronium ion Cl Cl + + - - Cl Cl+ Fe Cl Cl Cl Fe Cl Cl Fe Cl4 Cl Cl Chlorine Ferric chloride A molecular complex An ion pair (a Lewis (a Lewis with a positive charge containing a base) acid) on ch lorine ch loronium ion Step 2: attack of -
Summary of Gas Cylinder and Permeation Tube Standard Reference Materials Issued by the National Bureau of Standards
A111D3 TTbS?? o z C/J NBS SPECIAL PUBLICATION 260-108 o ^EAU U.S. DEPARTMENT OF COMMERCE/National Bureau of Standards Standard Reference Materials: Summary of Gas Cylinder and Permeation Tube Standard Reference Materials Issued by the National Bureau of Standards QC 100 U57 R. Mavrodineanu and T. E. Gills 260-108 1987 m he National Bureau of Standards' was established by an act of Congress on March 3, 1901. The Bureau's overall goal i s t0 strengthen and advance the nation's science and technology and facilitate their effective application for public benefit. To this end, the Bureau conducts research to assure international competitiveness and leadership of U.S. industry, science arid technology. NBS work involves development and transfer of measurements, standards and related science and technology, in support of continually improving U.S. productivity, product quality and reliability, innovation and underlying science and engineering. The Bureau's technical work is performed by the National Measurement Laboratory, the National Engineering Laboratory, the Institute for Computer Sciences and Technology, and the Institute for Materials Science and Engineering. The National Measurement Laboratory Provides the national system of physical and chemical measurement; • Basic Standards 2 coordinates the system with measurement systems of other nations and • Radiation Research furnishes essential services leading to accurate and uniform physical and • Chemical Physics chemical measurement throughout the Nation's scientific community, • Analytical Chemistry industry, and commerce; provides advisory and research services to other Government agencies; conducts physical and chemical research; develops, produces, and distributes Standard Reference Materials; provides calibration services; and manages the National Standard Reference Data System. -
(12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen Et Al
USOO8603526B2 (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen et al. (45) Date of Patent: Dec. 10, 2013 (54) PHARMACEUTICAL COMPOSITIONS 2008. O152595 A1 6/2008 Emigh et al. RESISTANT TO ABUSE 2008. O166407 A1 7/2008 Shalaby et al. 2008/0299.199 A1 12/2008 Bar-Shalom et al. 2008/0311205 A1 12/2008 Habib et al. (75) Inventors: Peter Holm Tygesen, Smoerum (DK); 2009/0022790 A1 1/2009 Flath et al. Jan Martin Oevergaard, Frederikssund 2010/0203129 A1 8/2010 Andersen et al. (DK); Karsten Lindhardt, Haslev (DK); 2010/0204259 A1 8/2010 Tygesen et al. Louise Inoka Lyhne-versen, Gentofte 2010/0239667 A1 9/2010 Hemmingsen et al. (DK); Martin Rex Olsen, Holbaek 2010, O291205 A1 11/2010 Downie et al. (DK); Anne-Mette Haahr, Birkeroed 2011 O159100 A1 6/2011 Andersen et al. (DK); Jacob Aas Hoellund-Jensen, FOREIGN PATENT DOCUMENTS Frederikssund (DK); Pemille Kristine Hoeyrup Hemmingsen, Bagsvaerd DE 20 2006 014131 1, 2007 (DK) EP O435,726 8, 1991 EP O493513 7, 1992 EP O406315 11, 1992 (73) Assignee: Egalet Ltd., London (GB) EP 1213014 6, 2002 WO WO 89,09066 10, 1989 (*) Notice: Subject to any disclaimer, the term of this WO WO91,040 15 4f1991 patent is extended or adjusted under 35 WO WO95/22962 8, 1995 U.S.C. 154(b) by 489 days. WO WO99,51208 10, 1999 WO WOOOf 41704 T 2000 WO WO 03/024426 3, 2003 (21) Appl. No.: 12/701,429 WO WOO3,O24429 3, 2003 WO WOO3,O24430 3, 2003 (22) Filed: Feb. -
1,1,1-Trichloroethane (CASRN 71-55-6) | IRIS
Integrated Risk Information System (IRIS) U.S. Environmental Protection Agency Chemical Assessment Summary National Center for Environmental Assessment 1,1,1-Trichloroethane; CASRN 71-55-6 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data, as outlined in the IRIS assessment development process. Sections I (Health Hazard Assessments for Noncarcinogenic Effects) and II (Carcinogenicity Assessment for Lifetime Exposure) present the conclusions that were reached during the assessment development process. Supporting information and explanations of the methods used to derive the values given in IRIS are provided in the guidance documents located on the IRIS website. STATUS OF DATA FOR 1,1,1-Trichloroethane File First On-Line 03/31/1987 Category (section) Assessment Available? Last Revised Oral RfD (I.A.) Acute Oral RfD (I.A.1.) qualitative discussion 09/28/2007 Short-term Oral RfD (I.A.2.) qualitative discussion 09/28/2007 Subchronic Oral RfD (I.A.3.) yes 09/28/2007 Chronic Oral RfD (I.A.4.) yes 09/28/2007 Inhalation RfC (I.B.) Acute Inhalation RfC (I.B.1.) yes 09/28/2007 Short-term Inhalation RfC (I.B.2.) yes 09/28/2007 Subchronic Inhalation RfC (I.B.3.) yes 09/28/2007 1 Integrated Risk Information System (IRIS) U.S. Environmental Protection Agency Chemical Assessment Summary National Center for Environmental Assessment Category (section) Assessment Available? Last Revised Chronic Inhalation RfC (I.B.4.) yes 09/28/2007 Carcinogenicity Assessment (II.) yes 09/28/2007 I. Health Hazard Assessments for Noncarcinogenic Effects I.A. -
BENZENE AS a LARVICIDE for SCREW WORMS1 the Larval Stage
BENZENE AS A LARVICIDE FOR SCREW WORMS1 By D. C. PARMAN Assistant Entomologist, Investigations of Insects Affecting the Health of Animals, Bureau of Entomology, United States Department of Agriculture INTRODUCTION The larval stage of CocMiomyia macellaria Fab., generally known amonff stock raisers in the Southwest as the screw worm, causes con- siderable loss to the livestock industry, estimated as high as $5,000,000 in some years. It has been apparent that the larvicides used to kill the worms are either toxic to the animal or at least in most cases detrimental to the healing of the wounds. This toxicity was at first attributed to the screw worm, but as many cases were ob- served where the animal was practically consumed by the larvae and still lived until the loss of olood or injury to some vital organ brought de^th, it was surmised that the treatments with larvicides were the cause of many deaths. During the summer of 1916 syste- matic work was begun to find a more efficient larvicide than the phenols and chloroform which were generally used. At first an attempt was made to add something to these larvicides to counteract the toxic properties. As this was not successful it was deemed best to look for a chemical that might be used with more satis- factory results. Several chemical groups were studied for possible larvicides. EXPERIMENTAL PROCEDURE All available chemicals with possible larvicidal value were selected for laboratory tests to determine whether they would kill the larvae of the screw-worm fly. The first tests were made by pouring the chemical on a number of larvae in a tube, or dusting on just enough to cover the larvae. -
Pharmacological Classification of the Abuse-Related Discriminative
Ashdin Publishing Journal of Drug and Alcohol Research ASHDIN Vol. 3 (2014), Article ID 235839, 10 pages publishing doi:10.4303/jdar/235839 Research Article Pharmacological Classification of the Abuse-Related Discriminative Stimulus Effects of Trichloroethylene Vapor Keith L. Shelton and Katherine L. Nicholson Department of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, P.O. Box 980613, Richmond, VA 23298, USA Address correspondence to Keith L. Shelton, [email protected] Received 10 December 2013; Revised 2 January 2014; Accepted 27 January 2014 Copyright © 2014 Keith L. Shelton and Katherine L. Nicholson. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Inhalants are distinguished as a class primarily based upon common means of administration suggests a homogeneity of a shared route of administration. Grouping inhalants according to mechanism and behavioral effects that may be scientifically their abuse-related in vivo pharmacological effects using the drug unwarranted. As an illustration of the inadequacy of this discrimination procedure has the potential to provide a more relevant classification scheme to the research and treatment community. simplistic taxonomic approach, consider the fact that if a Mice were trained to differentiate the introceptive effects of the similar system was applied to other common drugs of abuse, trichloroethylene vapor from air using an operant procedure. then tobacco, crack cocaine, and marijuana would be treated Trichloroethylene is a chlorinated hydrocarbon solvent once used as a single category. Instead, other classes of abused drugs as an anesthetic as well as in glues and other consumer products. -
Reactions of Aromatic Compounds Just Like an Alkene, Benzene Has Clouds of Electrons Above and Below Its Sigma Bond Framework
Reactions of Aromatic Compounds Just like an alkene, benzene has clouds of electrons above and below its sigma bond framework. Although the electrons are in a stable aromatic system, they are still available for reaction with strong electrophiles. This generates a carbocation which is resonance stabilized (but not aromatic). This cation is called a sigma complex because the electrophile is joined to the benzene ring through a new sigma bond. The sigma complex (also called an arenium ion) is not aromatic since it contains an sp3 carbon (which disrupts the required loop of p orbitals). Ch17 Reactions of Aromatic Compounds (landscape).docx Page1 The loss of aromaticity required to form the sigma complex explains the highly endothermic nature of the first step. (That is why we require strong electrophiles for reaction). The sigma complex wishes to regain its aromaticity, and it may do so by either a reversal of the first step (i.e. regenerate the starting material) or by loss of the proton on the sp3 carbon (leading to a substitution product). When a reaction proceeds this way, it is electrophilic aromatic substitution. There are a wide variety of electrophiles that can be introduced into a benzene ring in this way, and so electrophilic aromatic substitution is a very important method for the synthesis of substituted aromatic compounds. Ch17 Reactions of Aromatic Compounds (landscape).docx Page2 Bromination of Benzene Bromination follows the same general mechanism for the electrophilic aromatic substitution (EAS). Bromine itself is not electrophilic enough to react with benzene. But the addition of a strong Lewis acid (electron pair acceptor), such as FeBr3, catalyses the reaction, and leads to the substitution product. -
Formation of Nitrous Oxide
1461 No. 5069 DECEMBER 24. 1966 NATURE E-+ CCI. --->- ECC1 3 + Cl- Formation of Nitrous Oxide THE mechanism of formation of nitrous oxide from am The tightly bound .CCI3 group will not be removable in monium nitrate is attributable to the recognized thermal the normal biochemical reaction and the enzyme molecule dissociation of ammonium salts followed in this instance will be inactivated. by nitration of ammonia and decomposition of the ensuing This process of enzyme inactivation could, in principle, nitramide. The mechanism of this latter stage has been account for the toxicity of carbon tetrachloride and studied by various workers, notably by Marlies and La similar compounds and also of many insecticides. The Merl. Further, the decomposition of methyl nitramido postulated mechanism would also explain the observation to tho oxide and methyl alcohol is on record 2. by Butlerl3 that carbon tetrachloride is reduced in vivo As the nitration process, for example, of benzene, is to chloroform. Thus a proportion of .CCls radicals may commonly accompanied by some oxidation, the possibility react with sites other than the enzyme and abstract, of its OCClllTcnce in the preparation of nitrous oxide with for example, a hydrogen atom from a hydroxyl group or formation of nitrogen peroxide is not surprising and from a sulphydryl group. The latter exchange does technically well recognized. It has also recently been the appear to be possible from energy considerations. subject of public concern. D(RS-H) = 89 kcalJmole (ref. 14), .J. KENNER D(CI3G-H) = 91·4 kcalJmole (ref. 9) 41 Burlington Road, I have found that the activation energy of the electron Withington, capture reaction in chloroform vapour Manchester 20. -
Physiologically-Based Pharmacokinetic Modelling of Infant
AAS Open Research AAS Open Research 2018, 1:16 Last updated: 21 MAY 2018 RESEARCH ARTICLE Physiologically-based pharmacokinetic modelling of infant exposure to efavirenz through breastfeeding [version 1; referees: 1 approved with reservations] Adeniyi Olagunju 1,2, Rajith K. R. Rajoli 2, Shakir A. Atoyebi1, Saye Khoo2, Andrew Owen2, Marco Siccardi2 1Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria 2Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, L69 3GF, UK v1 First published: 14 May 2018, 1:16 (doi: 10.12688/aasopenres.12860.1) Open Peer Review Latest published: 14 May 2018, 1:16 (doi: 10.12688/aasopenres.12860.1) Referee Status: Abstract Background: Very little is known about the level of infant exposure to many drugs commonly used during breastfeeding. The aim of this study was to Invited Referees develop a physiologically-based pharmacokinetic (PBPK) model for predicting 1 infant exposure to maternal efavirenz through breastmilk. Methods: A breastfeeding PBPK model combining whole-body maternal and version 1 infant sub-models was constructed from drug-specific and system parameters published report affecting drug disposition using mathematical descriptions. The model was 14 May 2018 validated against published data on the pharmacokinetics of efavirenz in nursing mother-infant pairs. Further simulations were conducted to assess 1 Jeffrey W. Fisher, US Food and Drug exposure in the context of the 400 mg reduced dose of efavirenz as well as Administration, USA best- and worse-case scenarios. Results: The model adequately described efavirenz pharmacokinetics, with over 80% of observed data points (203 matched breast milk and plasma pairs) Discuss this article within the predictive interval. -
Federal Register/Vol. 71, No. 34/Tuesday, February 21, 2006
Federal Register / Vol. 71, No. 34 / Tuesday, February 21, 2006 / Notices 8859 DEPARTMENT OF HEALTH AND DEPARTMENT OF HEALTH AND of the Public Health Service Act to HUMAN SERVICES HUMAN SERVICES conduct directly or by grants or contracts, research, experiments, and Office of the National Coordinator; Office of the National Coordinator; demonstrations relating to occupational American Health Information American Health Information safety and health and to mine health. Community Chronic Care Workgroup Community Consumer Empowerment The BSC shall provide guidance to the Meeting Workgroup Meeting Director, NIOSH on research and prevention programs. Specifically, the ACTION: Announcement of meeting. ACTION: Announcement of meeting. board shall provide guidance on the institute’s research activities related to SUMMARY: SUMMARY: This notice announces the This notice announces the developing and evaluating hypotheses, third meeting of the American Health third meeting of the American Health Information Community Consumer systematically documenting findings Information Community Chronic Care and disseminating results. The board Workgroup in accordance with the Empowerment Workgroup in accordance with the Federal Advisory shall evaluate the degree to which the Federal Advisory Committee Act (Pub. activities of NIOSH: (1) Conform to L. 92–463, 5 U.S.C., App.) Committee Act (Pub. L. 92–463, 5 U.S.C., App.) appropriate scientific standards, (2) DATES: March 22, 2006 from 1 p.m. to address current, relevant needs, and (3) DATES: March 20, 2006 from 1 p.m. to 5 p.m. produce intended results. 5 p.m. ADDRESSES: Hubert H. Humphrey Matters to be Discussed: Agenda items ADDRESSES: Hubert H. Humphrey Building (200 Independence Ave., SW., include a report from the Director, Building (200 Independence Ave., SW., Washington, DC 20201), Conference NIOSH; progress report by BSC working Washington, DC 20201), Conference Room 705A. -
Lectures Covering Concentrated Topics in Emergency Medicine (Tems)
Lectures covering concentrated Topics in Emergency Medicine (TEMs) Section Week Title Topics Toxicology 007 External Decontamination and External decontamination Patient Stabilization Initial approach Airway management Patient control Drug interactions Anatomical distortion Advanced life support Alterations to standard therapy Prolonged resuscitation Organ donation Focused assessment History Vital signs Physical examination 008 Minimizing Absorption, Minimizing absorption Enhancing Elimination, and Syrup of ipecac Ancillary Testing Gastric lavage Activated charcoal Cathartics Whole-bowel irrigation Enhancing elimination Chelation Multidose charcoal Hemodialysis and peritoneal dialysis Hemoperfusion Exchange transfusion Ancillary testing Toxicology screens Serum Urine Serum quantitation 009 Insecticides [17.01.20(b)] DEET Diquat and Paraquat Metaldehyde Methylbromide and other fumigants Nicotine Organophosphates [17.01.33] and carbamates Pyrethrins, pyrethroids, and organohalides 010 Rodenticides [17.01.20(c)] Anticoagulant [17.01.05] 4-hydroxycoumarins Indanediones Nonanticoagulant [excluding heavy metals] α-naphthylthiourea Boric acid Bromethalin Cholecalciferol Elemental phosphorus Fluroacetamide PNU Strychnine [17.01.37] 011 Hydrocarbons [17.01.23] Aliphatic Aromatic General Toluene Xylene Halogenated General Carbon tetrachloride Methylene chloride Trichloroethylene Pine Oil and Turpentine Polychlorinated biphenyls and related substances 012 Caustic & Corrosive Agents Ingestions Acid [17.01.14(a)] Alkali [17.01.14(b)] Other Disc batteries